Pulmonary embolism in COVID-19 patients: a French multicentre cohort study.
Betacoronavirus
COVID-19
Computed Tomography Angiography
/ methods
Coronavirus Infections
/ complications
Female
France
/ epidemiology
Hospitalization
/ trends
Humans
Incidence
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ complications
Pulmonary Embolism
/ diagnosis
Retrospective Studies
Risk Factors
SARS-CoV-2
Survival Rate
/ trends
COVID-19
Computed tomography angiography
Intensive care unit
Pulmonary embolism
Risk factors
Journal
European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
received:
03
05
2020
revised:
18
05
2020
accepted:
07
06
2020
pubmed:
14
7
2020
medline:
22
9
2020
entrez:
14
7
2020
Statut:
ppublish
Résumé
While pulmonary embolism (PE) appears to be a major issue in COVID-19, data remain sparse. We aimed to describe the risk factors and baseline characteristics of patients with PE in a cohort of COVID-19 patients. In a retrospective multicentre observational study, we included consecutive patients hospitalized for COVID-19. Patients without computed tomography pulmonary angiography (CTPA)-proven PE diagnosis and those who were directly admitted to an intensive care unit (ICU) were excluded. Among 1240 patients (58.1% men, mean age 64 ± 17 years), 103 (8.3%) patients had PE confirmed by CTPA. The ICU transfer and mechanical ventilation were significantly higher in the PE group (for both P < 0.001). In an univariable analysis, traditional venous thrombo-embolic risk factors were not associated with PE (P > 0.05), while patients under therapeutic dose anticoagulation before hospitalization or prophylactic dose anticoagulation introduced during hospitalization had lower PE occurrence [odds ratio (OR) 0.40, 95% confidence interval (CI) 0.14-0.91, P = 0.04; and OR 0.11, 95% CI 0.06-0.18, P < 0.001, respectively]. In a multivariable analysis, the following variables, also statistically significant in univariable analysis, were associated with PE: male gender (OR 1.03, 95% CI 1.003-1.069, P = 0.04), anticoagulation with a prophylactic dose (OR 0.83, 95% CI 0.79-0.85, P < 0.001) or a therapeutic dose (OR 0.87, 95% CI 0.82-0.92, P < 0.001), C-reactive protein (OR 1.03, 95% CI 1.01-1.04, P = 0.001), and time from symptom onset to hospitalization (OR 1.02, 95% CI 1.006-1.038, P = 0.002). PE risk factors in the COVID-19 context do not include traditional thrombo-embolic risk factors but rather independent clinical and biological findings at admission, including a major contribution to inflammation.
Identifiants
pubmed: 32656565
pii: 5870571
doi: 10.1093/eurheartj/ehaa500
pmc: PMC7528952
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3058-3068Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
Références
Eur Heart J. 2020 May 14;41(19):1858
pubmed: 32227120
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
Circulation. 2020 Jul 14;142(2):184-186
pubmed: 32330083
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
J Am Coll Cardiol. 2020 Jul 7;76(1):122-124
pubmed: 32387623
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Lancet Infect Dis. 2020 Oct;20(10):1135-1140
pubmed: 32526193
Lancet Rheumatol. 2020 Jul;2(7):e437-e445
pubmed: 32835247
Radiology. 2020 Sep;296(3):E186-E188
pubmed: 32324103
Eur Radiol. 2020 Sep;30(9):4903-4909
pubmed: 32314058
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
Radiology. 2020 Sep;296(3):E189-E191
pubmed: 32324102
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Vasc Surg Venous Lymphat Disord. 2019 May;7(3):317-324
pubmed: 30477976
Eur Heart J. 2020 May 14;41(19):1859
pubmed: 32282027
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Eur Heart J. 2020 Jul 14;41(27):2516-2518
pubmed: 32320040
Eur Heart J. 2020 May 14;41(19):1788-1790
pubmed: 32242895